Fig. 6
From: MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1
Arecoline induced DNMT3B activity and repressed ANK1 and miR-486-3p expression a: qRT-PCR analysis showing the expression level of ANK1 in OKF4/hTERT cells after treatment with 100 μM of arecoline for 5 days (mean ± SD). b: qRT-PCR analysis showing the expression level of miR-486-3p in OKF4/hTERT cells after treatment with 100 μM of arecoline for 5 days (mean ± SD; *p < 0.05). c: qRT-PCR (left) and western blot (right) analysis of DDR1 level in OKF4/hTERT cells after treatment with 100 μM of arecoline for 5 days. d: Heat map of DNMT1, DNMT3A and DNMT3B expression in 40 OSCC tissue pairs (GSE37991). Red, overexpression; green, downexpression. e: ChIP assay of ANK1 promoter region was performed with OKF4/hTERT cells using anti-DNMT3A antibody, anti-DNMT3B antibody or control IgG antibody as indicated. f: The methylation index (AVG Beta) of ANK1 promoter CpG islands from 40 matched pairs of human OSCC tissues was quantitativelydetermined using whole genome methylation data GSE38823 (mean ± SD; ***p < 0.001). g: Microarray intensity of miR-486-3p expression from 40 matched pairs of human OSCC tissues (mean ± SD; ***p < 0.001). h: Correlations between miR-486-3p expression and DNA methylation status of the ANK1 (AVG Beta) (n = 40). i: Correlations between DDR1 expression and DNA methylation status of the ANK1 (AVG Beta) (n = 40)